Celularity, Inc. (NASDAQ:CELU) Shares Shorted: Short Interest Down 56.7% in September

Celularity, Inc. (NASDAQ:CELU) was the target of a significant decrease in short interest in September. As of September 15th, there was short interest totaling 821,020 shares, a decrease of 56.7% from the August 31st total of 1,897,722 shares. Currently, 3.4% of the company’s stock are short sold. Based on an average trading volume of 393,553 shares, the days-to-cover ratio is currently 2.1 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of Celularity from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Celularity presently has an average rating of “Sell”.

Celularity Stock Down 2.1%

Shares of CELU opened at $1.37 on Wednesday. The business’s fifty day moving average is $1.10 and its 200 day moving average is $1.01. Celularity has a 12-month low of $0.56 and a 12-month high of $2.55. The stock has a market cap of $39.66 million, a P/E ratio of -0.41 and a beta of 0.79.

Celularity (NASDAQ:CELU) last released its quarterly earnings data on Tuesday, September 29th. The company reported $0.02 earnings per share for the quarter. The business had revenue of $3.85 million for the quarter.

Institutional Trading of Celularity

An institutional investor recently bought a new stake in Celularity stock. C V Starr & Co. Inc. bought a new stake in Celularity, Inc. (NASDAQ:CELU) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 764,069 shares of the company’s stock, valued at approximately $1,582,000. Celularity makes up approximately 0.8% of C V Starr & Co. Inc.’s investment portfolio, making the stock its 4th biggest position. C V Starr & Co. Inc. owned approximately 2.64% of Celularity at the end of the most recent reporting period. 19.02% of the stock is owned by institutional investors and hedge funds.

Celularity Company Profile

Celularity, Inc is a biotechnology company developing allogeneic cell therapies and biomaterial products derived from human placenta. The company’s research focuses on using placental cells and tissues to address unmet needs in oncology, immune-mediated diseases and regenerative medicine.

Celularity’s therapeutic pipeline has included CYNK-001, an off-the-shelf natural killer cell therapy being investigated for certain blood cancers, as well as other engineered and unmodified placental-derived cell programs.